Details

Autor(en) / Beteiligte

• Wein, Sharon
• Taudon, Nicolas
• Maynadier, Marjorie
• Tran Van Ba, Christophe
• Margout, Delphine
• Bordat, Yann
• Fraisse, Laurent
• Wengelnik, Kai
• Cerdan, Rachel
• Bressolle-Gomeni, Françoise
• Vial, Henri J

Titel

High Accumulation and In Vivo Recycling of the New Antimalarial Albitiazolium Lead to Rapid Parasite Death

Ist Teil von

• Antimicrobial agents and chemotherapy, 2017-08, Vol.61 (8), p.00352-17

Ort / Verlag

United States: American Society for Microbiology

Erscheinungsjahr

2017

Quelle

Elektronische Zeitschriftenbibliothek (Open access)

Beschreibungen/Notizen

• Albitiazolium is the lead compound of bisthiazolium choline analogues and exerts powerful and antimalarial activities. Here we provide new insight into the fate of albitiazolium in mice and how it exerts its pharmacological activity. We show that the drug exhibits rapid and potent activity and has very favorable pharmacokinetic and pharmacodynamic properties. Pharmacokinetic studies in -infected mice indicated that albitiazolium rapidly and specifically accumulates to a great extent (cellular accumulation ratio, >150) in infected erythrocytes. Unexpectedly, plasma concentrations and the area under concentration-time curves increased by 15% and 69% when mice were infected at 0.9% and 8.9% parasitemia, respectively. Albitiazolium that had accumulated in infected erythrocytes and in the spleen was released into the plasma, where it was then available for another round of pharmacological activity. This recycling of the accumulated drug, after the rupture of the infected erythrocytes, likely extends its pharmacological effect. We also established a new viability assay in the -infected mouse model to discriminate between fast- and slow-acting antimalarials. We found that albitiazolium impaired parasite viability in less than 6 and 3 h at the ring and late stages, respectively, while parasite morphology was affected more belatedly. This highlights that viability and morphology are two parameters that can be differentially affected by a drug treatment, an element that should be taken into account when screening new antimalarial drugs.